Impact of M22 Synergistic Sequential Treatment (SST)

Completed · Not applicable

Conditions studied: Improvement of Wrinkles/Elastosis and/or Pigmentation

In brief

Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least 50% of the study population.

Key facts

Study ID

NCT02032771

Run by

Lumenis Be Ltd.

People needed

33

Starts

2014-01-01

Expected to finish

2016-02-01

Last updated by the study team

2016-09-16

Who can join

Age: 30 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to read, understand and provide written Informed Consent;
• Healthy adult, male or female, 30-65 years of age with Fitzpatrick-Goldman skin type I-V;
• Having suitable facial areas with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis Score of 3-6 to be treated;
• Having suitable facial areas with mild to moderate age/sun-related facial pigmentation
• Able and willing to comply with the treatment/follow-up schedule and requirements;
• Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.

You may not qualify if…

• Skin type VI
• Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding
• Heavy smoker (>1 pack of cigarettes a day)
• Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
• Use of photosensitive medication for which light exposure is contraindicated.
• Use of oral isotretinoin (Accutane®) within 3 months of initial treatment or during the course of the study. Note: skin must regain its normal degree of moisture prior to treatment.
• Having indurate acne in treated area.
• Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in treated area
• Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in treated area within 3 months of initial treatment or during the course of the study;
• Prior skin laser/light or another device treatment in treated area within 6 months of initial treatment or during the course of the study
• Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
• Prior use of Botox in treatment area within 6 months
• Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
• Any other surgery in treated area within 9 months of initial treatment or during the course of the study.
• Participation in a study of another investigational device or drug involving the same anatomical site within 3 months prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion
• History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
• Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma)
• Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on area to be treated during the course of treatment
• Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;
• Multiple dysplastic nevi in area to be treated
• Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to treatment (as per the subject's physician discretion)
• History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
• Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face.
• Pigmented lesion in the treated area that appears cancerous or is not deemed suitable for photo therapy, as determined by a dermatologist.
• Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process;

Where it is running

• Knight Dermatology Institute — Orlando, Florida, United States
• Study site — Konz, Rhineland-Palatinate, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.